Nvidia is bringing their artificial intelligence technology to Quantum-Si. And together, they want to disrupt the drug discovery process.

‍What’s happening:‍

• Quantum-Si (NASDAQ: QSI) and Nvidia (NASDAQ: NVDA) have launched a new partnership to advance the development of Quantum-Si’s new proprietary proteomics platform known as Proteus
  

The big idea:‍

• Proteus is capable of analyzing proteins in extreme detail and can rapidly process highly complex samples
  
• Quantum-Si has already been using Nvidia’s generative artificial intelligence model for chemistry BioNeMode to design new biomolecules and will further leverage Nvidia’s full stack of computing technology to develop new breakthroughs for drug discovery research
  

Why it matters:‍

• Quantum-Si’s Proteus platform could unlock significant breakthroughs in protein structures that could help identify drug targets much more easily and also potentially even reveal entirely new drug targets
  

Going deeper:‍

• Quantum-Si already has more than a thousand issued and pending patents around their existing protein sequencing technology, prior to the upcoming launch of their Proteus platform
  

Market reaction:‍

• Shares of Quantum-Si are up +154% since announcing their new partnership with Nvidia

‍